A comparative analysis of biomarker selection techniques by Dessì N et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 387673, 10 pages
http://dx.doi.org/10.1155/2013/387673
Research Article
A Comparative Analysis of Biomarker Selection Techniques
Nicoletta Dessì, Emanuele Pascariello, and Barbara Pes
Dipartimento di Matematica e Informatica, Universita` degli Studi di Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
Correspondence should be addressed to Barbara Pes; pes@unica.it
Received 23 April 2013; Revised 22 September 2013; Accepted 23 September 2013
Academic Editor: Euge´nio Ferreira
Copyright © 2013 Nicoletta Dess`ı et al.his is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Feature selection has become the essential step in biomarker discovery from high-dimensional genomics data. It is recognized that
diferent feature selection techniques may result in diferent set of biomarkers, that is, diferent groups of genes highly correlated
to a given pathological condition, but few direct comparisons exist which quantify these diferences in a systematic way. In this
paper, we propose a general methodology for comparing the outcomes of diferent selection techniques in the context of biomarker
discovery. he comparison is carried out along two dimensions: (i) measuring the similarity/dissimilarity of selected gene sets; (ii)
evaluating the implications of these diferences in terms of both predictive performance and stability of selected gene sets. As a case
study, we considered three benchmarks deriving fromDNAmicroarray experiments and conducted a comparative analysis among
eight selection methods, representatives of diferent classes of feature selection techniques. Our results show that the proposed
approach can provide useful insight about the pattern of agreement of biomarker discovery techniques.
1. Introduction
Biomarker discovery from high-dimensional genomics data
is a critical problem with numerous applications in biology
and medicine, such as diagnosis and treatment of complex
diseases at themolecular level. As reported in [1], a biomarker
can be deined as “a characteristic that is objectivelymeasured
and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacological responses to a
therapeutic intervention.”
he discovery of biomarkers is typically modeled as a fea-
ture selection problem, where the aim is to identify the most
discriminating features (i.e., genes) for a given classiication
task, for example, distinguishing between healthy and tumor
tissues or between diferent tumor stages.Whilemany feature
selection techniques have been proposed [2], they do not
necessarily identify the same feature subsets in the biomarker
discovery process: indeed, even for the same data, diferent
techniques can result in diferent groups of genes, raising
questions about the biological signiicance of the discovered
markers [3].
Surprisingly very few works in the literature have inves-
tigated, in a systematic way, the degree of similarity/dis-
similarity between the outputs of diferent feature selection
techniques in the context of biomarker discovery. Existing
studies mostly focus on comparing the outcomes of diferent
techniques in terms of predictive performance (see, e.g., [4,
5]), and, only recently, researchers have investigated the issue
of stability of feature selection techniques with respect to
sample variation [6, 7].
In this paper, we propose a general methodology for
comparing diferent approaches to biomarker selection. he
comparison is carried out along two dimensions: (i) mea-
suring the similarity/dissimilarity of selected gene sets; (ii)
evaluating the implications of these diferences in terms of
both predictive performance and stability of selected gene
sets. As regards the similarity analysis, our methodology
incorporates twoways of evaluating the degree of consistency
among the gene sets: similarity in terms of gene overlapping
and functional similarity. his twofold evaluation aims to
investigate in what measure the biological functions captured
by diferent gene sets can be similar, despite a limited
overlapping among these sets. As regards the analysis of
predictive performance and stability of selected biomarkers,
our approach leverages on best practices from the literature
[8, 9] and incorporates them into a uniied comparative
framework.
As a case study, we considered three benchmarks deriving
from DNAmicroarray experiments, that is, the Colon Tumor
dataset [10], the Leukemia dataset [11], and the Prostate
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dataset [12]. In the empirical analysis, eight selection meth-
ods were included as representative of diferent classes of
feature selection techniques. Speciically, we considered both
univariate approaches that evaluate the relevance of each
single gene independently from the others and multivariate
approaches that take into account interdependencies among
genes. Our results show that the adopted methodology can
provide useful insight about the pattern of agreement of
diferent biomarker selection methods.
he paper is organized as follows. Section 2 details the
methodology, motivating it in the context of the underlying
background. Section 3 illustrates the considered case study,
describing the datasets, the selection methods, and the
settings used in the experiments. he experimental results
are presented and discussed in Section 4. Finally, Section 5
contains some inal remarks and future research directions.
2. Background and Methodology
In this study we focus on feature selection methods that
produce a ranking of features based on their relevance for the
predictive task at hand. Referred in the following as rankers,
these methods assign a weight to each feature according to
some scoring criterion that evaluates the degree of correlation
between that feature and the target class. his weighting
process can be carried out in two ways [2]: evaluating each
feature independently from the others (univariate methods)
or taking into account feature dependencies (multivariate
methods). Once each feature has been weighted, a ranked
list is produced where features appear in descending order
of relevance: this list can be cut at a proper threshold point in
order to obtain a subset of highly predictive features.
In the context of gene selection, the resulting feature sub-
set can be interpreted as a signature that captures signiicant
knowledge for a given diagnostic task. Our aim here is to
compare, in a systematic way, the signatures produced by
diferent rankers; this comparison is carried out along two
dimensions, as detailed in the following.
2.1. Evaluating Similarity of Selected Gene Sets. Given a
dataset � with � instances and � features (i.e., genes), a
number � of rankers �� (� = 1, 2, . . . ,�) are applied to �:
each �� produces a ranked list � � (� = 1, 2, . . . ,�) where
the � features appear in descending order of relevance. As
illustrated in Figure 1, this results in � distinct ranked lists
each expressing a diferent ordering of the� genes.
When two lists � � and � � (�, � = 1, 2, . . . ,�) are cut at a
given threshold point �, the resulting gene sets �� and �� (�, � =
1, 2, . . . ,�), of the same size �, can be compared according
to some similarity index I. In particular, our methodol-
ogy incorporates two approaches to measure the degree of
similarity/dissimilarity among selected gene sets: similarity
in terms of gene overlapping (I-overlap) and functional
similarity(I-functional).
he similarity I-overlap between two sets �� and �� can be
expressed as the number of genes that are present in both sets,
that is, |�� ∩ ��|, properly normalized in the range [0, 1], with
0 meaning that there is no overlap between the two sets and 1
that the two sets are identical. As normalization factor, we use
|�� ∪ ��|, as in [8]. Ater computing the I-overlap value for
each pair of gene sets, we average over all pairwise similarity
comparisons to obtain an overall evaluation of the degree of
similarity between the� gene sets.
It has been observed, however, that the biological func-
tions captured by diferent gene sets can be similar, despite
a little degree of overlapping between these sets [13–15]. To
compare two gene sets in functional terms, we exploit gene
annotations from the Gene Ontology (GO) database [16],
which provides a set of controlled vocabularies (biological or
biochemical terms) describing gene products based on their
functions in the cell. Speciically, for each gene set �� (� =
1, 2, . . . ,�), we extract the list of molecular function GO
terms that annotate the � genes in the set.he resulting� lists
of GO terms are then compared, in pairs, using the similarity
measure (I-functional) proposed in [17] which considers not
only the overlap between the lists but also the semantic
relationships between GO terms.
2.2. Evaluating Predictive Performance and Stability of Selected
Gene Sets. he predictive performance of a candidate gene
set, that is, its capacity of discriminating a given target
class (e.g., a pathological state), can be measured inducing a
classiication model on that set and using some test instances
to evaluate this model in terms of metrics such as accuracy
or ROC area [18]. his is usually done in a cross-validation
setting, though it has been observed that it can produce
overoptimistic results on small sample size domains [19].
Instead, no well-established evaluation protocol exists for
measuring the stability of a biomarker selection algorithm,
that is, its robustness with respect to sample variation: small
changes in the original dataset should not afect the outcome
of the selection process in a signiicant way. Research work
on designing a suitable experimental procedure for testing
stability in high-dimensional/small sample size domains is
still ongoing [7], and inmost cases stability is not evaluated in
conjunction with predictive performance but in independent
experiments.
hemethodologywe adopt involves a single experimental
setup to jointly evaluate both stability and predictive perfor-
mance in the context of biomarker discovery. As illustrated
in Figure 2, we extract from the original dataset �, with �
instances and� features (i.e., genes), a number � of reduced
dataset �� (� = 1, 2, . . . , �), each containing � ⋅ � (with
� ∈ (0, 1)) instances randomly drawn from�.
Each of the previously considered rankers �� (� = 1,
2, . . . ,�) is then applied to each reduced datasets�� (� = 1,
2, . . . , �) in order to obtain a ranked list � �� and, ater cutting
the list at threshold �, a gene subset ���. he � subsets
selected by the ranker �� from the � reduced datasets are
then compared in terms of overlapping: the more similar (in
average) these subsets are, the more stable the ranker �� is.
We observe that the I-overlap measure is used in our
approach in a twofold way: to compare the subsets produced
by diferent rankers on the same dataset � and to compare
the subsets produced by the same ranker on diferent reduced
datasets drawn from �. Moreover, it should be observed
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Figure 2: Joint evaluation of stability and predictive performance.
that the recent literature suggests the Kuncheva index [20] as
a more suitable similarity measure in the context of stability
evaluation: it considers the degree of overlapping between
two feature subsets and introduces a correction term that
takes into account the probability that a feature is included
in those subsets purely by chance. his correction term,
however, does not afect the similarity value for feature
subsets of small size, as the ones considered in the context
of biomarker discovery [21].
To incorporate predictive performance evaluation in the
above experimental protocol, we build on each reduced
dataset �� (� = 1, 2, . . . , �) a classiication model based
on the gene set ��� selected by the �th ranker: the model
performance is then estimated on a test set �� containing
the fraction of instances of � not included in �� (i.e., (1 −
�) ⋅ � instances). As performance metric we use the AUC
(area under the ROC curve), as it synthesizes the information
of sensitivity and speciicity and provides a more reliable
estimate in the case of unbalanced class distribution [22].
By averaging the AUC performance of the � classiication
models induced on the P gene subsets selected by the ranker
��, we can evaluate the efectiveness of that ranker in iden-
tifying highly predictive gene sets. his approach overcomes
the risk of selection bias [23] since the test instances are not
considered in any way in the gene selection stage.
he above methodology ensures a joint evaluation of two
fundamental requirements of any biomarker selection tech-
nique, that is, stability with respect to sample variation and
efectiveness in terms of classiication results, enabling the
comparison of diferent techniques in a uniied framework.
3. Case Study: Datasets and Settings
Consistently with the methodology described in Section 2,
we conducted an empirical analysis on three benchmarks
deriving from DNAmicroarray experiments.
(i) Colon Tumor dataset [10], containing 62 biological
samples distinguished between tumor colon tissues
(40 samples) and normal colon tissues (22 samples);
each sample is described by the expression level of
2000 genes.
(ii) Leukemia dataset [11], containing 72 samples belong-
ing to patients sufering from acute myeloid leukemia
(25 samples) and acute lymphoblastic leukemia (47
samples); each sample is described by the expression
level of 7129 genes.
(iii) Prostate dataset [12], containing 102 samples difered
between healthy and tumor prostate tissues (50 and
52 samples, resp.); each sample is described by the
expression level of 12600 genes.
he task, in terms of feature selection, is to identify
the genes most useful in discriminating between cancerous
and normal tissues (Colon and Prostate datasets) or between
diferent tumor types (Leukemia dataset).
In our experiments, we compared � = 8 rankers that
are representative of diferent classes of selection methods.
In particular, we considered both univariate approaches,
where each feature is ranked individually, and multivariate
approaches that take into account feature dependencies.
Among the univariate techniques, we chose: chi Squared
(�2) [24] as representative of statistic methods; information
gain (IG) [25], symmetrical uncertainty (SU) [26], and gain
ratio (GR) [27] as representatives of entropic methods; and
inally OneR (OR) [28] as representative of methods that
incorporate a classiication technique (in this case, a simple
rule-based classiier).
Among the multivariate techniques, we considered Reli-
efF (RF) [29] and SVM-embedded feature selection [30]. he
basic idea of RF is to estimate the relevance of features based
on their ability to distinguish between instances that are near
to each other. Instead, SVM-embedded feature selection uses
a linear SVM classiier to derive a weight for each feature.
hen, based on their weights, the features can be ordered
from the most important to the less important (SVM ONE
approach). Moreover, a backward elimination strategy can
be adopted which iteratively removes the features with the
lowest weights and repeats the overall weighting process on
the remaining features (SVM RFE approach). he fraction
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Figure 3: Colon dataset: stability versus number of genes.
of features removed at each iteration, 10% in our experi-
ments, greatly inluences the computational complexity of the
method.
For all the above feature selection techniques we used the
implementation provided by the WEKA machine learning
environment [31]. To systematically evaluate the degree of
overlapping between the gene subsets selected by the consid-
ered rankers, we developed a sotware module that interfaces
with WEKA. In what concerns the functional aspects, the
similarity analysis was performed by the online tools available
at [32].
As regards the evaluation of predictive performance and
stability of selected gene subsets, the parameters of our
methodologywere set as follows: a number� = 20 of reduced
datasets were extracted from the original dataset, and each
reduced dataset contains a fraction � = 0.9 of the original
samples. he ranked lists produced on these datasets by the
� = 8 rankers were cut at diferent threshold points (� = 5,
� = 10, � = 20, � = 30, etc.) as to evaluate stability and
predictive performance for gene subsets of increasing size. In
evaluating the predictive performance, we used as induction
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Figure 4: Leukemia dataset: stability versus number of genes.
algorithm a linear SVM classiier, which is widely considered
the “best of class” method in the context of microarray data
analysis; speciically, we employed the SVM implementation
provided by WEKA.
4. Experimental Results and Discussion
In this section we present and discuss the most signiicant
experimental results. First, we concentrate on indings from
the similarity analysis among the gene subsets selected by
diferent rankers (see Section 2.1); then we examine the
results of the joint evaluation of stability and predictive
performance of selected gene subsets (see Section 2.2).
4.1. Results of Similarity Analysis. he similarity analysis was
irst performed in terms of gene overlapping; that is, we
used the I-overlap index to compare, in pairs, the subsets
produced by the rankingmethods presented in Section 3 (�2,
IG, SU, GR, OR, RF, SVM RFE, and SVM ONE). Table 1
shows the results of this comparison for gene subsets of size
� = 10. Speciically, for each of the considered datasets,
BioMed Research International 5
Table 1: Similarity in terms of gene overlapping.
(a) Colon dataset
CHI2 IG SU GR OR RF SVM RFE SVM ONE
CHI 00.081.034.045.034.076.076.02
IG 0.67 0.67 0.43 0.43 0.25 0.18 0.00
SU 0.67 0.67 0.54 0.33 0.43 0.18 0.00
GR 0.43 0.43 0.54 0.33 0.33 0.11 0.00
OR 0.54 0.43 0.33 0.33 0.33 0.05 0.00
RF 00.011.033.033.034.052.034.0
SVM RFE 11.011.050.011.081.081.081.0
SVM ONE 0.00 0.00 0.00 0.00 0.00 0.00 0.11
(b) Leukemia dataset
CHI2 IG SU GR OR RF
CHI 81.033.011128.02
IG 0.82 0.82 0.82 0.82 0.43 0.25
SU 1 0.82 1 1 0.33 0.18
GR 81.033.01128.01
OR 1 0.82 1 1 0.33 0.18
RF 52.033.033.033.034.033.0
SVM RFE
SVM ONE
11.0
0.18
0.11
11.0
0.11
34.0
33.052.081.081.081.052.081.0
SVM ONE 0.11 0.18 0.11 0.11 0.11 0.43 0.33
SVM RFE
(c) Prostate dataset
CHI2 IG SU GR OR RF
CHI 50.081.045.045.076.028.02
IG 0.82 0.67 0.54 0.43 0.18 0.05
SU 0.67 0.67 0.82 0.54 0.25 0.05
GR 0.54 0.54 0.82 0.43 0.18 0.00
OR 0.54 0.43 0.54 0.43 0.18 0.05
RF 11.081.081.052.081.081.0
SVM RFE
50.0
0.05
0.05
0.05
0.05
52.0
52.011.050.000.050.050.050.0
SVM ONE 0.05 0.05 0.05 0.05 0.05 0.25 0.25
SVM RFE SVM ONE
that is, (a) Colon, (b) Leukemia, and (c) Prostate, the results
are represented in a matricial form: each cell contains the I-
overlap value for the pair of subsets selected by the rankers
in the corresponding row and column. Diferent shades of
gray are used to highlight diferent similarity ranges: the
darker the gray, the higher the similarity values. he average
similarity over all pairwise comparisons is 0.28 forColon, 0.49
for Leukemia; and 0.29 for Prostate (excluding the cells in the
main diagonal where each subset is compared with itself).
Results in Table 1 give useful insight about the pattern
of agreement of the considered methods. As regards the
univariate approaches (i.e., �2, IG, SU, GR, and OR), irst
evidence is that the �2 statistic produces results quite similar
to entropic methods IG and SU (I-overlap ≥ 0.67 for all the
considered benchmarks). he other entropic method, that is,
GR, turns out very similar to both IG and SU in the Leukemia
dataset but exhibits a somewhat diferent behavior in the
other datasets, especiallyColonwhich is recognized as amore
noisy benchmark. Globally, the univariate methods are more
similar to each other than to the multivariate approaches
(i.e., RF, SVM RFE, and SVM ONE). In particular, the SVM-
embedded feature selection produces feature subsets that
overlap to a small extent (or do not overlap at all) with the
subsets selected by other methods.
As a further step, the same gene subsets of size � = 10
were compared in functional terms based on the molecular
function GO annotations of genes in each subset. Results of
this comparison are shown in Table 2. Again, for each dataset,
results are reported in amatricial form: each cell contains here
the I-functional value for a pair of subsets selected by the
considered ranking methods. he average similarity is 0.78
for Colon, 0.86 for Leukemia, and 0.79 for Prostate.
hough similarity values in Tables 1 and 2 are not directly
comparable, due to the diferent similarity measures, the
ontological analysis shows that the functions captured by
diferent gene subsets can be similar, despite a little degree
of overlapping between these subsets. Interestingly, even
two subsets with no genes in common may exhibit a fairly
high level of functional similarity. Hence, there may be
common functions shared across diferent subsets that are not
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Table 2: Functional similarity.
(a) Colon dataset
CHI2 IG SU GR OR RF SVM RFE SVM ONE
CHI 56.067.067.069.038.029.099.02
IG 0.99 0.93 0.84 0.95 0.74 0.76 0.66
SU 0.92 0.93 0.87 0.87 0.79 0.73 0.66
GR 0.83 0.84 0.87 0.83 0.73 0.69 0.63
OR 0.96 0.95 0.87 0.83 0.77 0.74 0.69
RF 36.036.077.037.097.047.067.0
SVM RFE 57.036.047.096.037.067.067.0
SVM ONE 0.65 0.66 0.66 0.63 0.69 0.63 0.75
(b) Leukemia dataset
CHI2 IG SU GR OR RF SVM RFE SVM ONE
CHI 67.077.028.011199.02
IG 0.99 0.99 0.99 0.99 0.83 0.78 0.77
SU 1 0.99 1 1 0.82 0.77 0.76
GR 67.077.028.01199.01
OR 1 0.99 1 1 0.82 0.77 0.76
RF 38.008.028.028.028.038.028.0
SVM RFE 68.008.077.077.077.087.077.0
SVM ONE 0.76 0.77 0.76 0.76 0.76 0.83 0.86
(c) Prostate dataset
CHI2 IG SU GR OR RF SVM RFE SVM ONE
CHI 27.017.077.079.009.069.089.02
IG 0.98 0.96 0.90 0.94 0.77 0.69 0.69
SU 0.96 0.96 0.95 0.95 0.79 0.70 0.70
GR 0.90 0.90 0.95 0.89 0.69 0.58 0.66
OR 0.97 0.94 0.95 0.89 0.79 0.72 0.72
RF 77.007.097.096.097.077.077.0
SVM RFE 86.007.027.085.007.096.017.0
SVM ONE 0.72 0.69 0.70 0.66 0.72 0.77 0.68
apparent on the individual gene level. his helps explain why
diferent selection methods can produce diferent biological
signatures: these signatures may be in some way “consistent,”
even if they do not contain the same genes.
4.2. Results about Stability and Predictive Performance. Ater
evaluating the degree of similarity/dissimilarity among the
outcomes of diferent ranking methods, we empirically
examined the implications of these diferences in terms of
both stability and predictive performance of selected gene
subsets. In Figures 3, 4, and 5 we summarize, respectively, for
Colon, Leukemia, and Prostate datasets, the results of stability
analysis on gene subsets of increasing size. As explained
in Section 2.2, the stability value was obtained, for a given
ranking method, as the average similarity (I-overlap) among
the gene subsets selected by this method from a number
� = 20 of reduced datasets randomly drawn from the original
dataset.
Among the univariate approaches (�2, IG, SU, GR, and
OR), �2 and the entropic methods IG and SU exhibit,
in each dataset, a similar trend in terms of stability, while
GR slightly deviates from the other entropic methods in the
Colon dataset. he worst performing univariate method is
OR, which always results in a poor stability irrespective of
the number of genes included in the subset. Among the
multivariate approaches (RF, SVM RFE, and SVM ONE), RF
outperforms the SVM-embedded feature selection in each
of the benchmarks here considered. In particular, though
SVM RFE is known in the literature [30, 33] as a very efective
feature selection technique, it exhibits the worst behavior in
terms of stability.
As regards the evaluation of predictive performance, we
trained a linear SVM classiier on each of the � = 20 gene
subsets (of a given size) selected by a given ranking method
from the reduced datasets randomly drawn from the original
dataset: these reduced datasets serve at this stage as train-
ing sets. he average AUC performance, measured on the
independent test sets (see Section 2.2), is shown in Figure 6
(Colon), Figure 7 (Leukemia), and Figure 8 (Prostate) for
both univariate (�2, IG, SU, GR, and OR) and multivariate
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Figure 5: Prostate dataset: stability versus number of genes.
methods (RF, SVM RFE, and SVM ONE); in each igure, the
AUC trend is reported for gene subsets of increasing size.
As we can see, �2 and entropic methods globally exhibit a
similar behavior, almost coincident in Leukemia and Prostate
datasets, with a slight superiority of IG in the more problem-
atic Colon dataset: here GR turns out to be, for subsets of
small-moderate size (<40), the worst performing univariate
method. Interestingly, the ORmethod performs well in terms
of AUC (even better than other univariate approaches, for
subsets of small size, in both Colon and Leukemia datasets),
though its behavior in terms of stability is quite poor.
As regards the AUC performance of multivariate
approaches, there is no method that univocally outperforms
the others, contrary to what is observed in the stability
analysis. In theProstate dataset, indeed, the threemultivariate
methods are almost equivalent, while greater diferences
can be observed in the Leukemia dataset and, even more,
in the Colon dataset. However, it is worth remarking that
SVM RFE, in all the considered benchmarks, is very efective
in identifying small subsets of highly predictive genes,
despite its very low stability. We also observe that RF,
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Figure 6: Colon dataset: AUC versus number of genes.
which is the more stable multivariate method, has globally a
good performance also in terms of AUC.
To conclude, a number of observations can be drawn
from the joint analysis of stability and AUC patterns of
the eight ranking methods considered in this study. As a
irst point, a high level of agreement exists between the
behavior of the statistical approach �2 and the behavior
of entropic approaches, especially SU and IG. However, in
the Colon dataset (which is recognized as a more chal-
lenging benchmark), the entropic method GR performs
worse, probably due to its higher sensitivity to noise [34].
Moreover, it is interesting to highlight that the less stable
methods, that is, OR in the univariate category and SVM RFE
in the multivariate category, are both capable of selecting
small-sized subsets of highly predictive genes. Such cases of
instability coupled with high predictive performance could
be explained in terms of redundancy within the full set
of genes: the dataset may contain various markers that are
highly correlated which might lead the algorithm to select
diferent genes on diferent samples [7]. Globally, �2, SU,
and IG, representatives of univariate approaches, and RF,
representative ofmultivariate approaches, seem to best satisfy
8 BioMed Research International
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Figure 7: Leukemia dataset: AUC versus number of genes.
the objective of jointly optimized stability and efectiveness of
selected biomarkers.
5. Concluding Remarks and Future
Research Directions
A methodology has been presented for comparing the out-
comes of diferent feature selection techniques in the context
of biomarker discovery. Leveraging on best practices from
the literature, the proposed approach enables a multifaceted
evaluation of the degree of consistency among the genetic
signatures selected by diferent techniques.
As a case study, three public benchmarks have been
used to empirically evaluate the pattern of agreement of
somepopular biomarker discoverymethods. For futurework,
further experiments will be performed using more datasets
as well as diferent selection methods. Moreover, diferent
similarity measures could be incorporated in our method-
ology, especially in what concerns the evaluation of the
functional similarity among signatures, which is recognized
as a controversial research problem [15].
CHI2
IG
SU
GR
OR
0.70
0.75
0.80
0.85
0.90
0.95
1.00
0 10 20 30 40 50
A
U
C
Number of genes
(a) Univariate ranking methods
RF
SVM RFE
SVM ONE
0.70
0.75
0.80
0.85
0.90
0.95
1.00
0 10 20 30 40 50
A
U
C
Number of genes
(b) Multivariate ranking methods
Figure 8: Prostate dataset: AUC versus number of genes.
We also observe that the approach presented in this paper
can be a starting point for deining a suitable “ensemble” strat-
egy for biomarker selection. Indeed, recent research eforts
attempt to combine multiple feature selection techniques,
instead of using a single one, in order to overcome the
intrinsic limitations of each technique and obtain a more
reliable “consensus” result (e.g., a consensus ranking or a
consensus subset containing the most frequently selected
features). However, this combination is oten made on an
“ad hoc” basis [35–39], depending on the speciic problem at
hand, without considering the degree of diversity/similarity
of the involved methods. In our opinion, instead, this impor-
tant aspect should not be neglected: it would not be beneicial,
indeed, to combine two or more techniques that give almost
identical results. On the contrary, in an ensemble perspective,
the aim should be to reach a consensus result amongmethods
that are capable of giving diferent and complementary
representations of the considered domain. On this premise,
our future research will explore suitable ways of combining
biomarker selection techniques on the basis of their degree
of diversity/similarity, as assessed according to the approach
here discussed.
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